Denarda Dangaj1, Marine Bruand1, Alizée J Grimm1, Catherine Ronet1, David Barras2, Priyanka A Duttagupta3, Evripidis Lanitis1, Jaikumar Duraiswamy4, Janos L Tanyi5, Fabian Benencia6, Jose Conejo-Garcia7, Hena R Ramay8, Kathleen T Montone9, Daniel J Powell5, Phyllis A Gimotty10, Andrea Facciabene5, Donald G Jackson11, Jeffrey S Weber12, Scott J Rodig13, Stephen F Hodi14, Lana E Kandalaft1, Melita Irving1, Lin Zhang5, Periklis Foukas15, Sylvie Rusakiewicz1, Mauro Delorenzi2, George Coukos16. 1. Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne 1066, Switzerland. 2. Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne 1066, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland. 3. Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; University of Chicago, Knapp Center for Biomedical Discovery, Department of Hematology & Oncology, Chicago, IL 60637, USA. 4. Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Division of Cell and Gene Therapy, OTAT/CBER/FDA, Silver Spring, MD 20993, USA. 5. Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. 6. Russ College of Engineering and Technology, Ohio University, Athens, OH 45701, USA. 7. Department of Immunology and Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. 8. SIB Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland; International Microbiome Centre, University of Calgary, Calgary, AB, Canada. 9. Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. 10. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. 11. Bristol-Myers Squibb, Princeton, NJ 08540, USA. 12. Laura and Isaac Perlmutter Cancer Center, New York University, 522 First Avenue, Room 1310 Smilow Building, New York, NY 10016, USA. 13. Department of Pathology, Brigham & Women's Hospital, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 14. Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 15. Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne 1066, Switzerland; 2nd Department of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens 12464, Greece. 16. Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne 1066, Switzerland. Electronic address: george.coukos@chuv.ch.
Abstract
We investigated the role of chemokines in regulating T cell accumulation in solid tumors. CCL5 and CXCL9 overexpression was associated with CD8+ T cell infiltration in solid tumors. T cell infiltration required tumor cell-derived CCL5 and was amplified by IFN-γ-inducible, myeloid cell-secreted CXCL9. CCL5 and CXCL9 coexpression revealed immunoreactive tumors with prolonged survival and response to checkpoint blockade. Loss of CCL5 expression in human tumors was associated with epigenetic silencing through DNA methylation. Reduction of CCL5 expression caused tumor-infiltrating lymphocyte (TIL) desertification, whereas forced CCL5 expression prevented Cxcl9 expression and TILs loss, and attenuated tumor growth in mice through IFN-γ. The cooperation between tumor-derived CCL5 and IFN-γ-inducible CXCR3 ligands secreted by myeloid cells is key for orchestrating T cell infiltration in immunoreactive and immunoresponsive tumors.
We investigated the role of chemokines in regulating T cell accumulation in pan class="Disease">solid tumors. pan class="Gene">CCL5 and CXCL9 overexpression was associated with CD8+ T cell infiltration in solid tumors. T cell infiltration required tumor cell-derived CCL5 and was amplified by IFN-γ-inducible, myeloid cell-secreted CXCL9. CCL5 and CXCL9 coexpression revealed immunoreactive tumors with prolonged survival and response to checkpoint blockade. Loss of CCL5 expression in humantumors was associated with epigenetic silencing through DNA methylation. Reduction of CCL5 expression caused tumor-infiltrating lymphocyte (TIL) desertification, whereas forced CCL5 expression prevented Cxcl9 expression and TILs loss, and attenuated tumor growth in mice through IFN-γ. The cooperation between tumor-derived CCL5 and IFN-γ-inducible CXCR3 ligands secreted by myeloid cells is key for orchestrating T cell infiltration in immunoreactive and immunoresponsive tumors.
Authors: Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg Journal: Science Date: 2002-09-19 Impact factor: 47.728
Authors: Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski Journal: Cancer Res Date: 2009-03-17 Impact factor: 12.701
Authors: Selma Ugurel; David Schrama; Gunhild Keller; Dirk Schadendorf; Eva-Bettina Bröcker; Roland Houben; Marc Zapatka; Wolfram Fink; Howard L Kaufman; Jürgen C Becker Journal: Cancer Immunol Immunother Date: 2007-10-02 Impact factor: 6.968
Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Janis V de la Iglesia; Robbert J C Slebos; Laura Martin-Gomez; Xuefeng Wang; Jamie K Teer; Aik Choon Tan; Travis A Gerke; Garrick Aden-Buie; Tessa van Veen; Jude Masannat; Ritu Chaudhary; Feifei Song; Michelle Fournier; Erin M Siegel; Matthew B Schabath; J Trad Wadsworth; Jimmy Caudell; Louis Harrison; Bruce M Wenig; Jose Conejo-Garcia; Juan C Hernandez-Prera; Christine H Chung Journal: Clin Cancer Res Date: 2019-12-17 Impact factor: 12.531
Authors: Paul A Clark; Raghava N Sriramaneni; Amber M Bates; Won Jong Jin; Justin C Jagodinsky; Reinier Hernandez; Trang Le; Justin J Jeffery; Ian R Marsh; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Todd E Barnhart; Bryce R Anderson; Ishan Chakravarty; Ian S Arthur; KyungMann Kim; Jonathan W Engle; Bryan P Bednarz; Jamey P Weichert; Zachary S Morris Journal: Radiat Res Date: 2021-06-01 Impact factor: 2.841
Authors: Shuang Zhang; Sonia Iyer; Hao Ran; Igor Dolgalev; Shengqing Gu; Wei Wei; Connor J R Foster; Cynthia A Loomis; Narciso Olvera; Fanny Dao; Douglas A Levine; Robert A Weinberg; Benjamin G Neel Journal: Cancer Discov Date: 2020-11-06 Impact factor: 39.397